In summary, our study suggests that treatment with the HDAC inhibitor RGFP109 provides benefits on transcriptional dysregulation and motor skill learning and coordination deficits, while not affecting the locomotor and anxiety-like deficits and the progressive brain atrophy in the R6/1 mice. The gene discussed is HDAC9; the disease is Anxiety.